Eton Pharmaceuticals Submits New Drug Application for DS-200
Eton Pharmaceuticals, Inc. (ETON)
Last eton pharmaceuticals, inc. earnings: 3/5 04:02 pm
Check Earnings Report
Company Research
Source: GlobeNewswire
DEER PARK, Ill., March 14, 2019 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc. (Nasdaq: ETON), today announced that the Company has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for DS-200 via the Rolling Review process. DS-200 was previously granted Fast Track Designation by the FDA. This important designation is intended to speed the availability of drugs that treat serious conditions and demonstrate the potential to address an unmet medical need. “The commencement of the NDA submission process for DS-200 marks an important milestone for Eton as we continue to progress DS-200 and our broader late stage pipeline with a new total of four products applications submitted to the FDA,” said Sean Brynjelsen, Chief Executive Officer of Eton Pharmaceuticals. “Our recent regulatory progress with DS-200 and our growing portfolio of programs is bringing Eton one step closer to making these important medicines available to patients in need. We look forw
Show less
Read more
Impact Snapshot
Event Time:
ETON
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ETON alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ETON alerts
High impacting Eton Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
ETON
News
- Relief Therapeutics Enters into Exclusive U.S. License and Supply Agreement with Eton Pharmaceuticals for PKU GOLIKE [Yahoo! Finance]Yahoo! Finance
- Eton Pharmaceuticals Announces Acquisition of PKU GOLIKE® for Phenylketonuria [Yahoo! Finance]Yahoo! Finance
- Eton Pharmaceuticals Announces Acquisition of PKU GOLIKE® for PhenylketonuriaGlobeNewswire
- Harrow Health Non-GAAP EPS of -$0.20 misses by $0.15, revenue of $36.36M misses by $1.5M [Seeking Alpha]Seeking Alpha
- Eton Pharmaceuticals, Inc. (NASDAQ:ETON) Q4 2023 Earnings Call Transcript [Yahoo! Finance]Yahoo! Finance
ETON
Earnings
- 3/14/24 - Miss
ETON
Sec Filings
- 3/26/24 - Form S-8
- 3/22/24 - Form 10-K/A
- 3/22/24 - Form 8-K
- ETON's page on the SEC website